Compare Quest Diagnostics Inc (DGX) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs EPR Properties — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while EPR Properties trades at $54.74 (market cap $4.17B). The key difference: Quest Diagnostics Inc is far larger — about 6.1× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and EPR Properties for 46 Days on average.
| DGX | EPR | |
|---|---|---|
Market Cap | $25.48B | $4.17B |
Volume | 941,866 | 992,716 |
Sector | Health | Real Estate |
52-Week High | $247.45 | $64.32 |
52-Week Low | $173.49 | $48.71 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | $31.23B | $7.68B |
Dividend Yield | 1.49% | 6.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
EPR Properties trades at $54.41, up 0.61% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT reported strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though Q1 2026 earnings missed expectations. Recent news highlights its appeal for income investors, with monthly dividends and diversification into theme parks and fitness.
Outlook is mixed: analyst consensus is a Buy with a $65.50 target, but technicals and a projected 2026 net income decline pose risks. The stock offers value at a P/E of 17.44 and high yield, yet investors face headwinds from rising Treasury yields and competitive pressures in the net lease REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
